Narrative review / 2015
A systematic review found no high-quality evidence that ascorbate supplementation enhances chemotherapy's antitumor effects or reduces its toxicity.
A systematic review of 34 studies evaluated the antitumor effects and toxicity of oral or intravenous ascorbate in cancer patients. Due to study heterogeneity, no meta-analyses were performed. No randomized controlled trials reported statistically significant improvements in overall or progression-free survival, or reduced toxicity, compared to control arms. Evidence suggesting antitumor effects was limited to case reports and observational or uncontrolled studies.
- Study type
- Systematic review
- Who was studied
- Cancer patients across 34 studies (5 RCTs [n = 322], 12 phase I/II trials [n = 287], 6 observational studies [n = 7,599], and 11 case reports [n = 267])
- What was measured
- Antitumor effects, overall survival, progression-free survival, and toxicity of ascorbate treatment
THE PAPER
Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.
Jacobs C, Hutton B, Ng T, Shorr R, Clemons M. Oncologist, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.